Prelude Therapeutics Incorporated
PRLD
$0.9021
$0.01551.75%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
4/25/2025
-
Globe Newswire
4/10/2025
-
Zacks Investment Research
3/28/2025
-
MarketBeat
3/27/2025
-
The Fly
3/19/2025
-
Simply Wall St
3/17/2025
-
Simply Wall St
3/16/2025
-
Ticker Report
3/15/2025
-
MarketBeat
3/11/2025
-
Ticker Report
3/11/2025
-
TipRanks Financial Blog
3/10/2025
-
GuruFocus
3/10/2025
-
The Fly
3/10/2025
-
The Fly
3/10/2025
-
Globe Newswire
3/5/2025
-
GuruFocus
3/5/2025
-
Globe Newswire
1/3/2025
-
MarketBeat
1/3/2025
-
Ticker Report
1/2/2025
-
MarketBeat
12/30/2024
-
Market News Video
12/28/2024
-
Ticker Report
12/27/2024
-
MarketBeat
12/26/2024
-
GuruFocus
12/26/2024
-
MarketBeat
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, March 10, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
302 467 1280
Address
175 Innovation Boulevard
Wilmington, DE 19805
Wilmington, DE 19805
Country
Year Founded
Business Description
Sector
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is...
more